| PUBLICATIONS (Ranked by Impact Factor of the Journal) | Characteristics of Borrelia hermsii Infection in Human Hematopoietic Stem Cell-Engrafted Mice Mirror Those of Human Relapsing Fever Researchers examined Borrelia hermsii infection in human hematopoietic stem cell-engrafted nonobese diabetic/SCID/IL-2Rγnull mice: “human immune system mice”. [Proc Natl Acad Sci USA] Abstract | Press Release Rapamycin Combined with TGF-β Converts Human Invariant NKT Cells into Suppressive Foxp3+ Regulatory Cells In this study, researchers report that invariant NKT (iNKT) cells can express Foxp3 once they have been exposed to TGF-β. Foxp3 was expressed by iNKT cells from both peripheral and cord blood. [J Immunol] Abstract Human Umbilical Cord Blood-Derived Stromal Cells Regulate the Foxp3 Expression of Regulatory T Cells through the TGF-β1/Smad3 Pathway Researchers isolated a novel population from among CD34+ cells in their laboratory, referred to as human umbilical cord blood-derived stromal cells, which exert an immunosuppressive effect and can notably increase Foxp3 expression in regulatory T cells. [Cell Biochem Biophys] Abstract Valproic Acid Affects the Engraftment of TPO-Expanded Cord Blood Cells in NOD/SCID Mice Researchers evaluated the effect of valproic acid, in combination with thrombopoietin (TPO), on the viability and expansion of cord blood-hematopoietic stem and progenitor cells and on short- and long-term engraftability in the NOD/SCID mouse model. [Exp Cell Res] Abstract Hematopoietic Stem Cell Expansion Facilitates Multilineage Engraftment in a Nonhuman Primate Cord Blood Transplantation Model Researchers wished to establish a nonhuman primate cord blood transplantation model that would allow them to test various hematopoietic stem cell expansion and gene therapy strategies. [Exp Hematol] Abstract Hematopoietic and Myeloprotective Activities of an Acidic Angelica sinensis Polysaccharide on Human CD34+ Stem Cells This study aimed to separate and identify the major hematopoietic fraction from Angelica sinensis polysaccharides (ASPS), and to investigate the myeloprotective activity of the major bioactive fraction of ASPS as a possible supporting agent for cancer treatments. [J Ethnopharmacol] Abstract Effects of Mixed Feeder Cells on the Expansion of CD34+ Cells Synergistic effects of mesenchymal stem cells isolated from bone marrow, umbilical cord blood and periosteum, and fibroblasts as mixed feeder cells on the expansion of hematopoietic progenitor cells were investigated in serum- and exogenous cytokine-free conditions. [J Biosci Bioeng] Abstract A Novel Potent Fas Agonist for Selective Depletion of Tumor Cells in Hematopoietic Transplants Here scientists propose the use of a novel Fas agonist with potent pro-apoptotic activity, termed MegaFasL, as an effective ex-vivo purging agent. [Blood Cancer J] Abstract |
| SCIENCE NEWS | Therapy Improves Stem Cell Engraftment in Umbilical Cord Blood Transplant Recipients A therapy involving a natural compound may improve the ability of stem cells from umbilical cord blood to engraft in patients receiving a stem cell transplant for cancer or other diseases. [Press release from the Dana-Farber Cancer Institute discussing research presented at the 53rd Annual Meeting of the American Society of Hematology, San Diego] Press Release Fate Therapeutics Announces Promising Data from Phase Ib Study of ProHema Fate Therapeutics, Inc. announced promising clinical results from a Phase Ib trial of ProHema (FT1050-enhanced umbilical cord blood) as part of double-umbilical cord blood transplants in adult patients with hematologic malignancies who have undergone reduced-intensity conditioning therapy. [Press release from Fate Therapeutics, Inc. discussing research presented at the 53rd Annual Meeting of the American Society of Hematology, San Diego] Press Release Study Points to Novel Way to Improve Outcomes from Umbilical Cord Blood Transplants A new method to boost the number of immune cells in umbilical cord blood prior to cord blood transplants for cancer patients appears to lead to a quicker rebuilding of a new immune system in the patient’s body than with a conventional cord blood transplant procedure. [Press release from the Perelman School of Medicine at the University of Pennsylvania discussing research presented at the 53rd Annual Meeting of the American Society of Hematology, San Diego] Press Release |
|
|
|